Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein

Blood

Volumn 88, Issue 6, 1996, Pages 2219-2227

  Urashima, Mitsuyoshi ^b   Ogata, Atsushi ^b   Chauhan, Dharminder ^b   Vidriales, Maria B ^b   Teoh, Gerrard ^b   Hoshi, Yasutaka ^b   Schlossman, Robert L ^b   DeCaprio, James A ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD40 ANTIGEN; ELONGATION FACTOR 2; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; RETINOBLASTOMA PROTEIN;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DEPHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

EID: 0029837401     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.6.2219.bloodjournal8862219     Document Type: Article

References (59)

1. Kishimoto T: The biology of interleukin-6. Blood 74:1, 1989
2. Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, Yamamura Y: T cell-replacing factor (TFR)-induced IgG secretion in human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127:412, 1981
3. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T: Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82:5490, 1985
4. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF2/IL6 for human multiple myeloma. Nature 332:83, 1988
5. Anderson KC, Jones RC, Morimoto C, Leavitt P, Barut B: Response of purified myeloma cells to hematopoietic growth factors. Blood 73:1915, 1989
6. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81:3357, 1993
7. Barut B, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, Fingeroth J, Anderson KC: Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk Res 15:951, 1992
8. Hitzler J, Martinez-Valdez H, Bergsagel D, Minden MD: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-MY1-7 established from patients with advanced stage of the disease. Blood 78:1996, 1991
9. Schwab M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princler GL, Kung H: Disruption by interferon-α of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterogenous down-regulation of IL-6 receptor α- and β-chains. J Clin Invest 94:2317, 1994
10. Levy Y, Tsapis A, Brouet JC: Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 88:696, 1991
11. Klein B, Zhang XZ-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:512, 1989
12. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266, 1989
13. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone A, Marchisio C: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
14. Zhang XG, Gaillard JP, Robillard N, Lu AY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
15. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82:3712, 1993
16. Ahsmann EJM, Lokhorst HM, Dekker AW, Bloem AC: Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 79:2068, 1992
17. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248, 1995
18. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A: Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85:487, 1995
19. Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F, Takatsuki K: Expression of Fas/Apo-I (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86:1939, 1995
20. Bataille R, Jourdan M, Zhang X-G, Klein B: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity of plasma cell dyscrasias. J Clin Invest 84:2008, 1989
21. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H: Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77: 2794, 1991
22. Ballester OF, Moscinski, LC, Lyman GH, Chancy JV, Saba HI, Spiers ASD, Klein B: High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 83: 1903, 1994
23. Pelliniemi T-T, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhara A, Lakso M, Lahtinen R: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 85: 765, 1995
24. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198, 1991
25. Hubert DM, Kopf M, Mock BA, Kohler G, Rudikoff S: Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 182: 243, 1995
26. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakao N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 86: 7547, 1989
27. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 89: 232, 1994
28. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, Huang C-M, Livingston DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58: 1085, 1989
29. Mittnacht S, Weinberg RA: G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65: 381, 1991
30. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323, 1995
31. Chellappan SP, Hiebert S, Mudryi M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053, 1991
32. LaThangue NB; DRTF1/E2F: An expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem Sci 19:108, 1994
33. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G: Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 8:1280, 1994
34. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, Pileri A, Dalla-Favera R: Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758, 1994
35. Juge-Morineau N, Mellerin M-P, Francois S, Rapp M-J, Harousseau J-L, Amiot M, Bataille R: High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 91:664, 1995
36. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC: Transforming growth factor β1: Differential effects on multiple myeloma versus normal B cells. Blood 87:1928, 1996
37. Jernberg H, Nilsson K, Zech L, Lutz D, Nowotny H, Scheirer W: Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958, and U-1996). Blood 69:1605, 1987
38. Urashima M, Hasegawa N, Kamijo M, Shishikura A, Kato Y, Hoshi Y, Akatsuka JI, Maekawa K: Establishment of a human pro-B cell line (JKB-1) and its differentiation on preestablished bone marrow stromal cell layer. Am J Hematol 46:112, 1994
39. Sato T, Fuse A, Eguchi M, Hayashi Y, Ryo R, Adachi M, Kishimoto Y, Teramura M, Mizoguchi H, Shima Y: Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryocytic leukemia. Br J Haematol 72:184, 1989
40. Fuse A, Kakuda T, Shima Y, Van Damme J, Billiau A, Sato T: Interleukin 6, a possible autocrine growth and differentiation factor for the human megakaryocytic cell line, CMK. Br J Haematol 77:32, 1991
41. Koike M, Ishino K, Ikuta T, Huh N, Kuroki T: Growth enhancement of normal human keratinocytes by the antisense oligonucleotide of retinoblastoma susceptibility gene. Oncogene 10:117, 1995
42. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Breaseh-Anderson S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell costimulatory activity. EMBO J 11:4313, 1992
43. Urashima M, Chauhan D, Hatzianni M, Ogata A, Hollenbaugh D, Aruffo A, Anderson KC: CD40 ligand triggers interleukin-6-mediated B cell differentiation. Leuk Res (in press)
44. Wang JYJ, Knudsen ES, Welch PJ: The retinoblastoma tumor suppressor protein. Adv Cancer Res 64:25, 1994
45. Ogata A, Chauhan D, Urashima M, Dedera D, Hatziyanni M, Vidriales MB, Anderson KC: Interleukin-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activated protein kinase cascade, (submitted)
46. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
47. DeBoer CJ, Schuuring E, Dreef E, Peters G, Bartek J, Kluin PM, vanKrieken JHJM: Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 86:2715, 1995
48. Hirama T, Koeffler PH: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841, 1995
49. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR: The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053, 1991
50. Chen-Kiang S, Hsu W, Natkunam Y, Zhang X: Nuclear signaling by interleukin-6. Curr Opin Immunol 5:124, 1993
51. Santhanam U, Ray A, Sehgal P: Repression of interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad USA 88:7605, 1991
52. Robbins PD, Horowitz JM, Mulligan RC: Negative regulation of human c-fos expression by the retinoblastoma gene product. Nature 346:668, 1990
53. Ray A, LaForge K, Sehgal PB: On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inf Motif) occlusion. Mol Cell Biol 10:5736, 1990
54. Adnanet J, Shao ZZ, Robbins PD: The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J Biol Chem 270:8837, 1995
55. MacLead SL, Bellido TM, Epstein J, Manolagas SC, Barlogie B, Hardin JW: Transcription factor binding to IL-6 promotor correlates with IL-6 production by 6 multiple myeloma cell lines. Proc Am Ass Cane Res 36:3187a, 1995 (abstr)
56. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggers interleukin-6 secretion in multiple myeloma. Blood 85:1903, 1995
57. Zhu Y-M, Bradbury D, Russell N: Decreased retinoblastoma protein expression in acute myeloblastic leukemia is associated with the autologous proliferation of clonogenic blasts. Br J Haematol 86:533, 1994
58. Zhu Y-M, Bradbury DA, Keith FJ, Russell N: Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia 8:1982, 1994
59. Weide R, Tiemann M, Pfluger K-H, Koppler H, Parvizl B, Wacker H-H, Kreipe H-H, Havemann K, Parwaresch MR: Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. Leukemia 8:97, 1994